| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4467653
Max Phase: Preclinical
Molecular Formula: C16H18O2
Molecular Weight: 242.32
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: CCCCCc1ccc2cc(C(=O)O)ccc2c1
Standard InChI: InChI=1S/C16H18O2/c1-2-3-4-5-12-6-7-14-11-15(16(17)18)9-8-13(14)10-12/h6-11H,2-5H2,1H3,(H,17,18)
Standard InChI Key: VKNDODSBNIPGNL-UHFFFAOYSA-N
Associated Targets(non-human)
Grin2a Glutamate [NMDA] receptor subunit epsilon 1 (165 Activities)
Grin2b Glutamate [NMDA] receptor subunit epsilon 2 (915 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Grin2c Glutamate [NMDA] receptor subunit epsilon 3 (367 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Grin2d Glutamate [NMDA] receptor subunit epsilon 4 (130 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Grin1 Glutamate NMDA receptor; Grin1/Grin2a (798 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Grin1 Glutamate NMDA receptor; Grin1/Grin2b (1028 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Grin1 Glutamate NMDA receptor; Grin1/Grin2c (1127 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Grin1 Ionotropic glutamate receptor NMDA 1/2D (870 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 242.32 | Molecular Weight (Monoisotopic): 242.1307 | AlogP: 4.27 | #Rotatable Bonds: 5 |
| Polar Surface Area: 37.30 | Molecular Species: ACID | HBA: 1 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 2 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 3.99 | CX Basic pKa: | CX LogP: 4.91 | CX LogD: 1.75 |
| Aromatic Rings: 2 | Heavy Atoms: 18 | QED Weighted: 0.79 | Np Likeness Score: 0.16 |
References
| 1. Irvine MW, Fang G, Sapkota K, Burnell ES, Volianskis A, Costa BM, Culley G, Collingridge GL, Monaghan DT, Jane DE.. (2019) Investigation of the structural requirements for N-methyl-D-aspartate receptor positive and negative allosteric modulators based on 2-naphthoic acid., 164 [PMID:30622023] [10.1016/j.ejmech.2018.12.054] |
Source
Source(1):